Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.
暂无分享,去创建一个
[1] G. Nabel,et al. Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma. , 1997, The New England journal of medicine.
[2] A. Haase,et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells , 1997, Journal of virology.
[3] P. Vereerstraeten,et al. Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence. , 1996, Transplantation.
[4] E. Operskalski,et al. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma–associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission , 1996, Nature Medicine.
[5] J. Phair,et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma , 1996, Nature Medicine.
[6] W. Zhong,et al. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Phair,et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. , 1996, The Journal of infectious diseases.
[8] J. C. Martin,et al. Cidofovir, a New Agent with Potent Anti-Herpesvirus Activity , 1996 .
[9] S. Rafii,et al. Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells , 1996, The Journal of experimental medicine.
[10] M. McGrath,et al. Lytic growth of Kaposi's sarcoma–associated herpesvirus (human herpesvirus 8) in culture , 1996, Nature Medicine.
[11] D R Hoover,et al. Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma , 1996, AIDS.
[12] E. Cesarman,et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae , 1996, Journal of virology.
[13] C. Boshoff,et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells , 1995, Nature Medicine.
[14] C. Boshoff,et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma , 1995, The Lancet.
[15] D. Costagliola,et al. Can antiviral agents decrease the occurrence of Kaposi's sarcoma? , 1995, The Lancet.
[16] S. Franceschi,et al. HIV transmission, and Kaposi's sarcoma among European women , 1995, AIDS.
[17] S. Franceschi,et al. Risk for Kaposi's sarcoma among Italian women with AIDS. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[18] E. Cesarman,et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. , 1995, The New England journal of medicine.
[19] P. Moore,et al. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. , 1995, The New England journal of medicine.
[20] E. Cesarman,et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.
[21] H. Stellbrink,et al. Kaposi's sarcoma in HIV infected women in Germany: more evidence for sexual transmission. A report of 10 cases and review of the literature. , 1994, Genitourinary medicine.
[22] B. Kohler,et al. Cancer incidence trends in women at high risk of human immunodeficiency virus (HIV) infection , 1993, International journal of cancer.
[23] D. Farge. Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. , 1993, The European journal of medicine.
[24] P. Lietman,et al. Clinical pharmacology: foscarnet. , 1992, American Journal of Medicine.
[25] S. Vasavanonda,et al. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease , 1991, Antimicrobial Agents and Chemotherapy.
[26] C. Vogel,et al. Kaposi's sarcoma: a comparison of classical, endemic, and epidemic forms. , 1984, Seminars in oncology.
[27] E. Clercq. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections , 1996 .
[28] L. Morfeldt,et al. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. , 1994, Scandinavian journal of infectious diseases.
[29] J. C. Martin,et al. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. , 1992, Molecular pharmacology.
[30] D. Watts. Antiviral agents. , 1992, Obstetrics and gynecology clinics of North America.
[31] J. Kahn,et al. AIDS-associated Kaposi's sarcoma. , 1990, AIDS clinical review.
[32] V. Samsonov,et al. [Epidemiology of Kaposi's sarcoma]. , 1985, Sovetskaia meditsina.